Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 20, 2022 1:41pm
122 Views
Post# 34837755

RE:RE:RE:POC

RE:RE:RE:POCMy view on the stock price right now, given what I wrote the other day and many times before that is that only few shareholders are ready to sell at the actual price, but the company still does not have the big news in oncology to move things up significantly. That being said, in my opinion it's great entry point for a new investor that did his due diligence on publicly available facts. The bet on oncology, given the other assets the company has is very cheap. Maybe some will wake up to that in the coming weeks.


TH1902 wrote: With all due respect SPCEO, the market doesn't believe anything positive has happened yet.  The senseless downgrades didn't help...lol...

I would like to believe we are under the radar, but if our news really was that good, we would have seen a reaction in the SP by now imo...more data points required to move the needle...

SPCEO1 wrote: Everyone will have their opinion on this but my read is we re already at a point where it is reasonably likely the key attributes for the success of TH-1902 are in place and th ekey causes of failure are absent. 

palinc2000 wrote: A Google search of POC will lead to many many definitions none of which to suggest that we are at that point ATM ....
What is worst than fuzzy math is fuzzy science data ...
When and if POC is attained we will know just by seeing the market reaction $$$
 “Proof of concept may be defined as the earliest point in the drug development process at which the weight of evidence suggests that it is "reasonably likely" that the key attributes for success are present and the key causes of failure are absent.” POC is a key translational pivot point ...

 




<< Previous
Bullboard Posts
Next >>